BrainStorm Cell Therapeutic, a biotech company engaged in the development of adult stem cell therapies for the treatment of neurodegenerative diseases, has received notification from the European Patent Office (EPO) that it intends to grant to the company its patent application No. EP06766101.7.
This patent, entitled “Isolated Cells and Populations Comprising Same for the Treatment of CNS Diseases,” covers the method of production of the company’s proprietary technology that induces autologous bone marrow-derived mesenchymal stem cells (MSCs) to secrete large quantities of neurotrophic factors for the treatment of neurodegenerative diseases.
BrainStorm’s proprietary NurOwn™ stem cell therapy was developed from this differentiation method.
“We are confident that strengthening our patent portfolio in the European Union, together with leveraging our Orphan Drug status there, will position us well when we pursue European marketing approval of our stem cell therapy,” Chaim Lebovits, president of BrainStorm, stated in the press release. “This is a very exciting moment for BrainStorm as this is our first patent to receive a notice of allowance in Europe. In the EU there are about 50,000 ALS patients.”
BrainStorm is the exclusive worldwide licensee of these technologies from Ramot, the technology transfer company of Tel Aviv University.
For more information visit www.brainstorm-cell.com
Let us hear your thoughts below: